Urocortin 2 EIA kit - Cosmo Bio Co.,Ltd.

Antibodies

>

Urocortin 2 EIA kit

Catalog No.: YII-YK191-EX
Size: 1KIT
Price: ¥76000
$1014
antigen/source: Urocortin 2
Description: Synthetic
catalog info: Catalog 2012-p113
Storage: 4C
@
Immunogen: Rat
Reacts with: Rat
Measurement Range: 1.56 - 100 ng/mL
Purpose: This EIA kit is used for quantitative determination of urocortin 2 in rat plasma & serum samples. The kit is characterized by its sensitive quantification and high specificity. In addition, it has no influence by other components in samples. Rat urocortin 2 standard is highly purified synthetic product.
component: Antibody: X
Plate: X
Coating: X
Control: -
Standard: X
Labeling: X
Substrate: X
Others: X
1. Antibody coated plate 1 plate (96 wells)
2. Standard antigen 1 vial (100 ng )
3. Labeled antigen 1 vial
4. SA-HRP solution 1 bottle (12 mL )
5. Enzyme substrate solution 1 bottle (12 mL)
6. Stop solution 1 bottle (12 mL )
7. Buffer solution 1 bottle (25 mL )
8. Washing solution 1 bottle (50 mL )
9. Adhesive plate seal 3 pieces

Other:

 Supplementary 
Competitive
 Applicable sample 
Serum, Plasma
[Other]
Urocortin 2 (Ucn 2), also known as stresscopin-related peptide, is a novel predicted neuropeptide related to corticotropin-releasing factor (CRF). The peptide consistingof 38amino acid residues was first demonstrated to be expressed centrally and to bind selectively to type 2 CRF receptor (CRFR2). In the rodent, Ucn 2 transcripts were shown to be expressed in the discrete regions of the central nervous system including stress-related cell groups in the hypothalamus and brainstem. More recently, the expression of Ucn 2 transcripts was detected in the olfactory bulb, pituitary, cortex, hypothalamus, and spinal cord. Ucn 2 mRNA was also found to be expressed widely inavariety of peripheral tissues, most highly in the skin and skeletal muscle tissues. Ucn 2-like immunoreactivity was detected by RIA in acid extracts of mouse brain, muscle, and skin. Immunohistochemically Ucn 2 was found in both skin epidermis andadnexal structures and in the skeletal muscle myocytes. Ucn 2 gene transcription was stimulated in the hypothalamus and brainstem by glucocorticoid administration to the mouse and inhibited by removal of glucocorticoids by adrenalectomy, suggesting a putative link between the CRFR1 and CRFR2 pathways. On the other hand, in the rat a stressor-specific regulation of Ucn 2 mRNA expression in the hypothalamic paraventricular nucleus was demonstrated, which raised the possibility of a modularyrole of Ucn 2 mRNA in stress-induced alteration of anterior and posterior pituitary function, depending on the type of stress. Administration of dexamethasone to the mouse resulted in a decrease of Ucn 2 mRNA levels in the back skin region. Adrenalectomy signifcantly increased Ucn 2 mRNA levels in the skin, and the levels were reduced back to normal levels after corticoid replacement.
CRFR2 is found in cardiomyocytes and in endothelial and smooth muscle cells of the systemic vasculature. Ucn 2is expressed in the mouse cardiomyocytes. In the mouse, Ucn 2 treatment augmented heart rate, exhibited potent inotropic and lusitropic actions on the left ventricle, and induced a downward shift of the diastolic pressure-volume relation. Ucn 2 alsoreduced systemic arterial pressure, associated with a lowering of systemic arterial elastance and systemic vascular resistance. The effects of Ucn 2 were specific to CRFR2 function and independent of beta-adrenergic receptors. These experiments demonstrated thepotent cardiovascular physiologic actions of Ucn 2 in the both wild-type and cardiomyopathic mice and support a potential beneficial use of Ucn 2 in congestive heart failure treatment. The use of Ucn 2 was also proposed to treat ischemicheart disease because of its potent cardioprotective effect in the mouse heart and its minimal impact on the hypothalamic stress axis.
Administration of Ucn 2 to the mouse prevented the loss of skeletal muscle mass resulting from disuse due to casting,corticosteroid treatment, and nerve damage. In addition, Ucn 2 treatment prevented the loss of skeletal muscle force and myocyte cross-sectional area that accompanied muscle mass losses resulting from disuse due to casting. In normal muscles ofthe mouse, Ucn 2 increased skeletal muscle mass and force. It was thus proposed that Ucn 2 might find utility in the treatment of skeletal muscle wasting diseases including age-related muscle loss or sarcopenia.
Mouse urocortin 2 (Ucn 2) is a new peptidepredicted from mouse cDNA sequence and its physiologic and pathophysiologic significance has not yet been fully elucidated. However, the experimental data presented to date provided evidence for the important physiologic roles of Ucn 2 and urgethe necessityof further investigation of the peptide from various points of view.
We have already developed mouse urocortin 2 (Ucn2) EIA kit (YK190) and mouse urocortin 3 (Ucn3) 3 EIA (YK200). This time, as a part of tools for urocortin research,ourlaboratory developed rat urocortin 2 (Ucn2) EIA kit (YK191), which highly specific for rat Ucn 2 with almost no crossreaction to Ucn 1 (mouse, rat), Ucn 2 (mouse), Ucn 3 (mouse), and CRF (mouse, rat, human). The kit can be used for measurement of Ucn 2 in rat plasmaor serum with high sensitivity. It will be a specifically useful tool for Ucn 2 research.


Reference:

•  Lewis K, Li C et al., (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA. 98, 7570-7575
•  Fukuta T, Takahashi K et al., (2005) Urocortin 1, urocortin3/stresscopin, and corticotropin- releasing factor receptors in human adrenal and its disorders. J Clin Endocrinol Metab. 90, 4671-4678
•  Takahashi K, Totsune K et al., (2004) Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab. 89, 1897-1903
•  Saruta M, Takahashi K et al., (2005) Urocortin3/stresscopin in human colon: possible modulators of gastrointestinal function during stressful conditions. Peptide. 26, 1196-1206
•  Li C, Vaughan J et al., (2002) Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci. 22, 991-1001
•  Li C, Chen P et al: (2003) Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretin. Endocrinology. 144, 3216-3224
•  Hsu SY and Hsueh AJ (2001) Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med. 7, 605-611
•  Brar BK, Jonassen AK et al., (2004) Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 145, 24-35
•  Chanalaris A , Lawrence KM et al., (2003) Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol. 35, 1295-1305
 
>